19.10.19: Start of Quiet Period
Start of Quiet PeriodLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 16, 2019 Category: Pharmaceuticals Source Type: news

30.10.19: Q3 2019 News Conference Call
Q3 2019 News Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 16, 2019 Category: Pharmaceuticals Source Type: news

30.10.19: Q3 2019 Investor Conference Call
Q3 2019 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 16, 2019 Category: Pharmaceuticals Source Type: news

07.11.19: Morningstar Management Behind the Moat Conference, Chicago, U.S.A.
Morningstar Management Behind the Moat Conference, Chicago, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 15, 2019 Category: Pharmaceuticals Source Type: news

21.11.19: CACIB's 8th Annual Industrial, Infrastructure and Utilities Credit Seminar, London, UK
CACIB's 8th Annual Industrial, Infrastructure and Utilities Credit Seminar, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 15, 2019 Category: Pharmaceuticals Source Type: news

13.11.19: Morgan Stanley Global Chemical and Agriculture Conference, Boston, U.S.A.
Morgan Stanley Global Chemical and Agriculture Conference, Boston, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news

18.11.19: DZ Bank Germany Conference, Frankfurt, Germany
DZ Bank Germany Conference, Frankfurt, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news

25.11.19: UBS German Senior Investor Day, Munich, Germany
UBS German Senior Investor Day, Munich, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news

26.11.19: Redburn CEO Conference, London, UK
Redburn CEO Conference, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news

14.10.19: Not intended for U.S. and UK Media
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patientsA new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTEmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news

01.10.19: Ertharin Cousin to become member of Bayer AG Supervisory Board
Ertharin Cousin to become member of Bayer AG Supervisory BoardInternational expert in the area of nutrition and agriculture / Cousin succeeds Thomas Ebeling, who stepped down at the end of Septembermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 1, 2019 Category: Pharmaceuticals Source Type: news

28.09.19: Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib's activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved...
Source: Bayer IR Newsfeed: Events - September 28, 2019 Category: Pharmaceuticals Source Type: news

23.09.19: Not intended for U.S. and UK Media
Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EUPrecision oncology treatment Vitrakvi® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively designed to treat TRK fusion cancer, is the first therapy in the EU with a tumor-agnostic indication / Larotrectinib provides high response rates and durable responses in adults and children with TRK fusion cancer, including primary CNS tumors and brain metastases / In studies, larotrectinib demonstr...
Source: Bayer IR Newsfeed: Events - September 24, 2019 Category: Pharmaceuticals Source Type: news

20.09.19: Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Bayer data at ESMO 2019 highlights innovation in cancer researchNew data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondro...
Source: Bayer IR Newsfeed: Events - September 20, 2019 Category: Pharmaceuticals Source Type: news

10.09.19: Changes to Board of Management structure as of January 1, 2020:
Bayer reduces size of Board of Management from seven to five membersmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 10, 2019 Category: Pharmaceuticals Source Type: news

02.09.19: Not intended for U.S. and UK Media - New guidelines from the European Society of Cardiology (ESC):
Xarelto™ 2.5 mg plus aspirin recommended for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromesClinical practice guidelines from the European Society of Cardiology (ESC) recommend Xarelto vascular dose (2.5 mg twice daily) plus aspirin low dose once daily in the management of patients with chronic coronary syndromes (CCS) as well as for patients with diabetes and lower extremity arterial disease / New guidelines include a change in nomenclature from 'stable coronary artery disease' to 'chronic coronary syndromes' to better reflect the continuous high risk of heart attacks, str...
Source: Bayer IR Newsfeed: Events - September 2, 2019 Category: Pharmaceuticals Source Type: news

02.09.19: Bayer completes sale of iconic Coppertone™ brand to Beiersdorf
Bayer completes sale of iconic Coppertone™ brand to BeiersdorfDivestiture enables Bayer to focus on core OTC businessmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 2, 2019 Category: Pharmaceuticals Source Type: news

20.08.19: Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars
Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollarsExit of Animal Health business completes the series of portfolio measures initiated by Bayer in November 2018 ahead of announced schedule / Enhances Bayer's focus as a global leader in life sciences mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 20, 2019 Category: Pharmaceuticals Source Type: news

08.08.19: Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Bayer acquires BlueRock Therapeutics to build leading position in cell therapyImplied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson's disease expected later this year / BlueRock Therapeutics to continue to operate as an independent companymehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 8, 2019 Category: Pharmaceuticals Source Type: news

27.08.19: Commerzbank Sector Conference, Frankfurt, Germany
Commerzbank Sector Conference, Frankfurt, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

05.09.19: Societe Generale European Angle Conference, Brussels, Belgium
Societe Generale European Angle Conference, Brussels, BelgiumLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

10.09.19: Credit Suisse Annual Basic Materials Conference, New York, U.S.A.
Credit Suisse Annual Basic Materials Conference, New York, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

16.09.19: Deutsche Bank German Corporate Conference, San Francisco, U.S.A.
Deutsche Bank German Corporate Conference, San Francisco, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

19.09.19: Bank of America Merrill Lynch Global Healthcare Conference, London, UK
Bank of America Merrill Lynch Global Healthcare Conference, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

25.09.19: Goldman Sachs and Berenberg German Corporate Conference, Munich, Germany
Goldman Sachs and Berenberg German Corporate Conference, Munich, GermanyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

26.09.19: JP Morgan Investor Forum, Milan, Italy
JP Morgan Investor Forum, Milan, ItalyLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

26.09.19: Bernstein Strategic Decision Conference, London, UK
Bernstein Strategic Decision Conference, London, UKLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

27.02.20: 2019 Annual Report
2019 Annual ReportLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

28.04.20: Annual Stockholders' Meeting 2020
Annual Stockholders' Meeting 2020Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

06.08.19: Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets
Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real AssetsCurrenta valued with an attractive enterprise value of EUR 3.5 billion (100%)mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 7, 2019 Category: Pharmaceuticals Source Type: news

31.07.19: Not intended for U.S. and UK Media
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancerDarolutamide was approved in the U.S. under the FDA Priority Review designation; approval granted three months ahead of target FDA action date / Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADTmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 31, 2019 Category: Pharmaceuticals Source Type: news

30.07.19: Second quarter of 2019:
Bayer on track in operational businessGroup sales increase by 0.9 percent (Fx & portfolio adj.) to 11.485 billion euros / EBITDA before special items advances by 24.7 percent to 2.927 billion euros / Crop Science sees sales decline (Fx & portfolio adj. and pro forma) in challenging environment but posts substantial earnings growth due to acquired business / Pharmaceuticals posts higher sales and strong earnings growth / Consumer Health increases sales and earnings / Net income falls by 49.1 percent to 404 million euros, held back by special items for restructuring and impairments / Core earnings per share increase ...
Source: Bayer IR Newsfeed: Events - July 30, 2019 Category: Pharmaceuticals Source Type: news

26.07.19: Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in EuropeRecommendation for approval for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Upon approval, larotrectinib would be the first therapy in Europe with a tumor-agnostic indication / CHMP opinion is based on pooled data showing that larotrectinib provides high and durable responses in adult and pediatric patients with TRK fusion cancer, including CNS tumors / Larotrectinib showed a favora...
Source: Bayer IR Newsfeed: Events - July 26, 2019 Category: Pharmaceuticals Source Type: news

22.07.19: Yellow Wood Partners to acquire iconic Dr. Scholl's™ brand from Bayer
Yellow Wood Partners to acquire iconic Dr. Scholl's™ brand from Bayermehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 22, 2019 Category: Pharmaceuticals Source Type: news

18.07.19: Not intended for U.S. and UK Media
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancerCombination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer / Companies plan indication-seeking trialmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 18, 2019 Category: Pharmaceuticals Source Type: news

30.07.19: Q2 2019 Investor Conference Call
Q2 2019 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 16, 2019 Category: Pharmaceuticals Source Type: news

16.07.19: Start of Quiet Period
Start of Quiet PeriodAll investor conferences (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 16, 2019 Category: Pharmaceuticals Source Type: news

08.07.19: Not intended for U.S. and UK Media - Important step towards improved treatment for children with venous thromboembolism
Rivaroxaban demonstrates strong efficacy and safety profile in phase III study in children with thromboembolismPhase III EINSTEIN-Jr. study in children concludes the largest pediatric thromboembolism program delivering results consistent with those in adults / Study shows a low risk of recurrent venous thromboembolism (VTE) in children treated with rivaroxaban compared with standard of care with low rates of bleeding / First phase III data on the use of a non-vitamin K oral anticoagulant (NOAC) in a large pediatric population / Study investigated a body weight-adjusted oral 20 mg equivalent dose of rivaroxaban for the prev...
Source: Bayer IR Newsfeed: Events - July 8, 2019 Category: Pharmaceuticals Source Type: news

02.07.19: LEO Pharma completes the acquisition of Bayer's prescription dermatology business
LEO Pharma completes the acquisition of Bayer's prescription dermatology businessmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 2, 2019 Category: Pharmaceuticals Source Type: news

01.07.19: Century Therapeutics launches with USD 250M financing for induced pluripotent stem cells (iPSC) allogeneic cell therapy platform
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cells (iPSC) allogeneic cell therapy platformCreated by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies / Leaps by Bayer leads investment round with USD 215 million commitment to develop next-generation immune oncology treatmentsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - July 1, 2019 Category: Pharmaceuticals Source Type: news

26.06.19: Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg as mediator
Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg as mediator mehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 26, 2019 Category: Pharmaceuticals Source Type: news

21.06.19: Not intended for U.S. and UK Media
Bayer initiates Phase III trial of Aflibercept to prevent blindness in premature infantsmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 21, 2019 Category: Pharmaceuticals Source Type: news

19.06.19: Not intended for U.S. and UK Media
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trialGBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm / Results from the Phase II REGOMA study (Lombardi G et al, Lancet Oncol, 2018) support further evaluation of regorafenib in patients with newly diagnosed and recurrent glioblastoma, the most aggressive form of brain cancer / Medical need remains high in glioblastoma as...
Source: Bayer IR Newsfeed: Events - June 19, 2019 Category: Pharmaceuticals Source Type: news

05.06.19: Roadshow Los Angeles (CA), U.S.A.
Roadshow Los Angeles (CA), U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news

01.08.19: Crop Science Summer Technology Showcase Day 1 (Chesterfield Research Center), St. Louis, MO, U.S.A.
Crop Science Summer Technology Showcase Day 1 (Chesterfield Research Center), St. Louis, MO, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news

02.08.19: Crop Science Summer Technology Showcase Day 2 (Jerseyville Agronomy Center), St. Louis, MO, U.S.A.
Crop Science Summer Technology Showcase Day 2 (Jerseyville Agronomy Center), St. Louis, MO, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news

03.06.19: Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019:
New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019In five TRK fusion cancer patients with brain metastases across different tumor histologies, the overall response rate was 60%, with disease control achieved in all patients / In 14 adult and pediatric patients with TRK fusion cancer with primary central nervous system (CNS) tumors (including high grade gliomas), the overall response rate was 36% including two complete responses / 71% of evaluable patients with primary CNS tumors experienced disease control for 24 weeks or more / First pros...
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news

04.06.19: Roadshow West Coast, U.S.A.
Roadshow West Coast, U.S.A.Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - June 4, 2019 Category: Pharmaceuticals Source Type: news

31.05.19: Not intended for U.S. and UK Media - 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Bayer's darolutamide plus androgen deprivation therapy (ADT) delays worsening of disease-related symptoms and maintains quality of life beyond end of study treatment compared to placebo plus ADT in men with non-metastatic castration-resistant prostate canResults of a new post-hoc analysis showed that treatment with darolutamide plus androgen deprivation therapy (ADT) delayed worsening of urinary and bowel symptoms versus placebo plus ADT / Exposure-adjusted incidences of treatment-emergent adverse events (TEAEs), including notably TEAEs associated with androgen receptor (AR) antagonists, were generally similar for daroluta...
Source: Bayer IR Newsfeed: Events - May 31, 2019 Category: Pharmaceuticals Source Type: news

22.05.19: Roadshow Warsaw, Poland
Roadshow Warsaw, PolandLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - May 22, 2019 Category: Pharmaceuticals Source Type: news